Literature DB >> 8649609

Intravenous administration of fosphenytoin: options for the management of seizures.

R E Ramsay1, J DeToledo.   

Abstract

Fosphenytoin is a water-soluble disodium phosphate ester of phenytoin that is converted in plasma to phenytoin. Fosphenytoin is compatible with most common i.v. solutions and can be administered safely through the i.m.route. An additional safety factor is the absence of propylene glycol in the fosphenytoin formulation. Propylene glycol is used as a vehicle in the i.v. phenytoin preparation and by itself may produce serious cardiovascular complications. Studies of the pharmacokinetics, safety, and tolerance of i.v. fosphenytoin have demonstrated that fosphenytoin produces phenytoin plasma concentrations similar to those achieved with oral and i.v. phenytoin, but without significant cardiovascular effects and only minimal discomfort at the injection site. Aside from local reactions, the most common adverse events associated with fosphenytoin have been pruritus and reactions typical of phenytoin (e.g., dizziness, somnolence, and ataxia). Fosphenytoin represents a significant advance in the treatment of patients with seizures who require parenteral therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649609     DOI: 10.1212/wnl.46.6_suppl_1.17s

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Managing status epilepticus. New drug offers real advantages.

Authors:  M T Heafield
Journal:  BMJ       Date:  2000-04-08

2.  Fosphenytoin in the emergency department.

Authors:  J Comes
Journal:  West J Med       Date:  1998-03

Review 3.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage.

Authors:  Haichen Wang; Junling Gao; Timothy F Lassiter; David L McDonagh; Huaxin Sheng; David S Warner; John R Lynch; Daniel T Laskowitz
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

5.  Trigeminal neuralgia : a guide to drug choice.

Authors:  W P Cheshire
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

6.  Animal models for the development of new neuropharmacological therapeutics in the status epilepticus.

Authors:  Ed Martín; Ma Pozo
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

7.  IV fosphenytoin in obese patients: Dosing strategies, safety, and efficacy.

Authors:  Sarah L Clark; Megan R Leloux; Ross A Dierkhising; Gregory D Cascino; Sara E Hocker
Journal:  Neurol Clin Pract       Date:  2017-02

Review 8.  Antiepileptic Drug Therapy for Status Epilepticus.

Authors:  Daeyoung Kim; Jae Moon Kim; Yong Won Cho; Kwang Ik Yang; Dong Wook Kim; Soon Tae Lee; Young Joo No; Jong Geun Seo; Jung Ick Byun; Kyung Wook Kang; Keun Tae Kim
Journal:  J Clin Neurol       Date:  2021-01       Impact factor: 3.077

Review 9.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.